

SPECIALTY QUANTITY LIMIT PROGRAM

VERZENIO (abemaciclib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Verzenio (abemaciclib) 50 mg tablet	56 tablets per 28 days	Breast Cancer: <ul style="list-style-type: none"> • When used in combination with fulvestrant, the recommended dose is 150 mg orally twice daily. • When used as monotherapy, the recommended dose of Verzenio is 200 mg orally twice daily. Dose Modifications for Adverse Reactions: <ul style="list-style-type: none"> • When a dose modification is required, each dose is decreased by a 50-mg increment (e.g., decrease from 150 mg twice daily to 100 mg twice daily). • Discontinue for patients unable to tolerate 50 mg twice daily.
Verzenio (abemaciclib) 100 mg tablet		
Verzenio (abemaciclib) 150 mg tablet		
Verzenio (abemaciclib) 200 mg tablet		

III. REFERENCE

1. Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; August 2018.